PeptideDB

Tubulin polymerization-IN-11 2470063-59-1

Tubulin polymerization-IN-11 2470063-59-1

CAS No.: 2470063-59-1

Tubulin polymerization-IN-11 is a novel and selective inhibitor of tubulin polymerization with an IC50 value of 3.4 µM.
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Tubulin polymerization-IN-11 is a novel and selective inhibitor of tubulin polymerization with an IC50 value of 3.4 µM. Antiproliferative activity is demonstrated by tubulin polymerization-IN-11. Apoptosis and cell cycle arrest are induced at the G2/M phase by tubulin polymerization-IN-11. Tubulin polymerization-IN-11 increases the expression of cleaved PARP while decreasing the expression of Bcl-2, p-cdc2, and cyclin B1.

Physicochemical Properties


Molecular Formula C22H22N4O4
Exact Mass 406.1641052
CAS # 2470063-59-1
Related CAS # 2470063-59-1
Appearance Typically exists as solid at room temperature
InChi Key UHDXUJRRMFTWMJ-UHFFFAOYSA-N
InChi Code

InChI=1S/C22H22N4O4/c1-27-17-7-5-13(9-16(17)23)14-6-8-20-24-25-22(26(20)12-14)15-10-18(28-2)21(30-4)19(11-15)29-3/h5-12H,23H2,1-4H3
Chemical Name

2-methoxy-5-[3-(3,4,5-trimethoxyphenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yl]aniline
Synonyms

Tubulin polymerization-IN-11
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


ln Vitro Tubulin polymerization-IN-11 (compound 7i) exhibits anti-proliferative activity against HeLa, HEK-293, A549, MCF-7, and T47D cells, with IC50 values of 0.012 and >100, respectively, over a 48-hour period. 10.40, 40.40, 27.91 µM, and 10.40 µM[1]. In the G2/M phase, tubulin polymerization-IN-11 (12, 24, 48 nM; 24 h) dose-dependently causes cellular inflammation and cell cycle events [1]. Polymerization of tubulin-IN-11 (12, 24, 24 h)
Cell Assay cell proliferation analysis [1]
Cell Types: HeLa, HEK- 48 nM; 24 h) reduces cyclin B1, p-cdc2, Bcl in a dose-based manner -2 protein levels and increase the expression of cleaved PARP protein [1]. 293, A549, MCF-7, T47D Cell
Tested Concentrations: 0-100 µM
Incubation Duration: 48 hrs (hours)
Experimental Results: demonstrated anti-proliferative activity against HeLa, HEK-293, A549, MCF, IC50 was 0.012, >100, 10.40, 40.40, 27.91 µM -7, T47D cells, respectively.

Cell cycle analysis [1]
Cell Types: HeLa Cell
Tested Concentrations: 12, 24, 48 nM
Incubation Duration: 24 h
Experimental Results: Induced cell cycle arrest in G2/M phase, cell percentages were 13.90%, 26.00% and 92.65% respectively. 12, 24, 48 nM.

Western Blot Analysis[1]
Cell Types: HeLa Cell
Tested Concentrations: 12, 24, 48 nM
Incubation Duration: 24 hrs (hours)
Experimental Results: Concentration-dependent reduction in cyclin B1 and p-cdc2 protein levels.

Apoptosis analysis [1]
Cell Types: HeLa Cell
Tested Concentrations: 12, 24, 48 nM
Incubation Duration: 24 h
Experimental Results: Induced apoptosis with the total numbers of early and late apoptotic cells were 8.44%, 26.87% and 53.3% at 12, 24, and 48 nM, respectively.
References [1]. Yang F, et al. Synthesis, and biological evaluation of 3,6-diaryl-[1,2,4]triazolo[4,3-a]pyridine analogues as new potent tubulin polymerization inhibitors. Eur J Med Chem. 2020 Oct 15;204:112625.

Solubility Data


Solubility (In Vitro) May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)